SentiMag® Intraoperative Comparison in Breast Cancer (SentiMagIC)
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093-0698
- University Of California San Diego Moores Cancer Center
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, United States, 94115
- UCSF Carol Franc Buck Breast Care Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Coordinated Health Breast Care Specialists
-
-
Texas
-
Dallas, Texas, United States, 75230
- Dallas Surgical Group
-
Houston, Texas, United States, 77030-4008
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with a diagnosis of primary breast cancer or subjects with pure ductal carcinoma in situ (DCIS).
- Subjects scheduled for surgical intervention, with a sentinel lymph node biopsy procedure being a part of the surgical plan.
- Subjects aged 18 years or more at the time of consent.
- Subjects with an ECOG (Eastern Cooperative Oncology Group) performance status of Grade 0 - 2.
- Subject has a clinical negative node status (i.e. T0-3, N0, M0).
Exclusion Criteria:
- The subject is pregnant or lactating.
- The subject has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes.
- The subject has a known hypersensitivity to Isosulfan Blue Dye.
- The subject has participated in another investigational drug study within 30 days of scheduled surgery.
- Subject has had either a) previous axilla surgery, b) reduction mammoplasty, or c) lymphatic function that is impaired in the surgeon's judgment.
- Subject has had preoperative radiation therapy to the affected breast or axilla.
- Subject has received a Feraheme® (ferumoxytol) Injection within the past 6 months.
- Subject has intolerance or hypersensitivity to iron or dextran compounds or to SiennaXP.
- Subject has an iron overload disease.
- Subject has pacemaker or other implantable device in the chest wall.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SiennaXP injection
Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye. Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe. |
Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
Other Names:
Injection of a single dose of isosulfan blue dye
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Detected Lymph Nodes
Time Frame: During surgical procedure <1 hour
|
The proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye
|
During surgical procedure <1 hour
|
|
Safety of SiennaXP and SentiMag® as Indicated by Adverse Events and Serious Adverse Events and Their Relatedness to the Detection Method or Procedure.
Time Frame: 3-6 weeks
|
Number of Participants with Adverse Events relating to Sienna XP Injection
|
3-6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nodal Concordance: Number of Nodes Identified by Both Test and Control Out of Nodes Identified by Control
Time Frame: Intraoperative <1 hour
|
The number of nodes identified by both SiennaXP and Control out of nodes identified by Control
|
Intraoperative <1 hour
|
|
Number of Participants With Lymph Nodes Detected by Combined Radioisotope,Blue Dye and Magnetic Technique
Time Frame: Intraoperative <1 hour
|
The per patient detection rate for a combination of all methods (magnetic, combined radioisotope and blue dye; radioisotope alone; blue dye alone)
|
Intraoperative <1 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michael D Alvarado, MD, University of CA, San Francisco Carol Franc Buck Breast Care, Dept of Surgery
Publications and helpful links
General Publications
- Douek M, Klaase J, Monypenny I, Kothari A, Zechmeister K, Brown D, Wyld L, Drew P, Garmo H, Agbaje O, Pankhurst Q, Anninga B, Grootendorst M, Ten Haken B, Hall-Craggs MA, Purushotham A, Pinder S; SentiMAG Trialists Group. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol. 2014 Apr;21(4):1237-45. doi: 10.1245/s10434-013-3379-6. Epub 2013 Dec 10.
- Thill M, Kurylcio A, Welter R, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014 Apr;23(2):175-9. doi: 10.1016/j.breast.2014.01.004. Epub 2014 Jan 29.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- US-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.